Steven Shayani, MD
Cardiovascular Disease · Carle Place, NYNPI 1306824008
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $258,767 of the $290,632 with a category attached, or 89.0%. Boehringer Ingelheim accounts for 65.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $59,887 and has fallen 63.2% since, to $22,032 in 2025. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 338 payments — averaging $859.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$189K
- Lilly USA, LLC$43K
- Amgen$35K
- Sanofi-aventis U.S. LLC$13K
- Regeneron Healthcare Solutions, Inc.$5K
- Pfizer$2K
- plus $4K from 14 others
Across 19 payments — averaging $3282.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$30K
- Amgen$24K
- Boehringer Ingelheim$8K
- Abbott$315
What the payments were for
- Consulting fees$6,2452%
- Speaking & faculty fees$258,76789%
- Travel & lodging$12,0434%
- Food & beverage$13,4785%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 150 | $188,971 |
| Lilly USA, LLC | 40 | $43,211 |
| Amgen | 51 | $35,097 |
| Sanofi-aventis U.S. LLC | 9 | $12,635 |
| Regeneron Healthcare Solutions, Inc. | 9 | $4,507 |
| Pfizer | 10 | $2,271 |
| Biotronik Inc. | 28 | $1,677 |
| Abbott | 5 | $553 |
| Johnson & Johnson | 13 | $543 |
| Medtronic(2 entities) | 4 | $459 |
| Boston Scientific | 3 | $158 |
| Bayer | 2 | $143 |
| Astellas Pharma US Inc | 1 | $99 |
| E.r. Squibb & Sons, L.L.C. | 3 | $63 |
| Novartis | 3 | $59 |
| Heartflow, Inc. | 2 | $57 |
| Terumo Medical Corporation | 2 | $57 |
| Scpharmaceuticals Inc. | 1 | $31 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $20 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$228,468
- Repatha$34,596
- PRALUENT$16,793
- ELIQUIS$2,125
- PRADAXA$545
- XARELTO$375
- CoreValve Evolut$180
- PRESSUREWIRE$150
- CARDIOMEMS$141
- CardioInsight$139
- Kerendia$132
- MitraClip System$130
- SYMPLICITY G3$125
- Watchman$119
- BioMonitor$118
- Mitra Clip system$108
How this compares
$290,632 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 117 | $176,390 |
| MounjaroTirzepatide | 83 | $158,569 |
| Repatha SureclickEvolocumab | 136 | $156,742 |
| XareltoRivaroxaban | 100 | $107,096 |
| EliquisApixaban | 93 | $103,206 |
| EntrestoSacubitril/Valsartan | 59 | $64,586 |
| OzempicSemaglutide | 24 | $48,206 |
| Praluent PenAlirocumab | 36 | $37,959 |
| MultaqDronedarone Hcl | 15 | $17,492 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 26 | $6,709 |
| BystolicNebivolol Hcl | 14 | $5,952 |
| Ezetimibe | 147 | $5,206 |
| Nebivolol Hcl | 76 | $5,066 |
| Rosuvastatin Calcium | 307 | $4,936 |
| Eplerenone | 57 | $4,488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $188,971 | $176,390117 claims |
| Lilly USA, LLCMounjaro | $43,211 | $158,56983 claims |
| Johnson & JohnsonXarelto | $543 | $107,096100 claims |
| PfizerEliquis | $2,271 | $103,20693 claims |
| NovartisEntresto | $59 | $64,58659 claims |
| Sanofi-aventis U.S. LLCMultaq | $12,635 | $17,49215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Carle Place
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.